The Northern Health Science Alliance (NHSA) in the UK has signed a memorandum of understanding (MoU) with Singapore-based firm Zicom MedTacc to boost the growth of the medtech sector in Northern England.
Under the terms of the strategic partnership, Singaporean medtech companies will come to Northern England for the development and internationalisation of new medical technology.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
These companies will be able to carry out British clinical validation and evaluate economic impact through the NHSA, while the Northern region will have access to new technologies and treatments.
NHSA CEO Dr Hakim Yadi said: “We have been working with Zicom MedTacc for the last two years.
“This MoU formalises our existing working relationship and will support us in establishing a more enduring partnership.
“This offers practical commercial opportunities for both medtech companies and life science researchers in Singapore, as well as in the North of England.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We hope it encourages collaboration between the two countries, which will enable companies from both geographies to expand into their reciprocal international markets.”
Yadi further added that the deal will aid Northern medtech diagnostic and digital health companies to launch their products in Asia Pacific countries through NHSA’s strategic partners in Singapore.
Through the deal, NHSA also intends to support high-skilled jobs and investment in the region over long-term.
Zicom MedTacc chief executive Kok Hwee said: “We have forged a close partnership with the NHSA and are confident that through the NHSA, we would be able to help more Singaporean healthcare and medical technology companies which are interested in establishing a presence in the North of England.
“Likewise, we are extremely delighted to be able to provide support to UK companies coming to Singapore to explore opportunities, be it research and clinical collaborations or as a launchpad for breaking into the Singapore or other Asian markets.”
